Efficacy of natalizumab in multiple sclerosis patients with high disease activity: a Danish nationwide study
Author:
Publisher
Wiley
Subject
Neurology (clinical),Neurology
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1468-1331.2008.02517.x/fullpdf
Reference8 articles.
1. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis;Polman;New England Journal of Medicine,2006
2. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis;Rudick;New England Journal of Medicine,2006
3. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy;Yousry;New England Journal of Medicine,2006
4. Quantifying the risks and benefits of natalizumab in relapsing multiple sclerosis;Dorsey;Neurology,2007
5. Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring;Kappos;Lancet Neurol,2007
Cited by 77 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Literature review and meta-analysis of natalizumab therapy for the treatment of highly active relapsing remitting multiple sclerosis in the ‘suboptimal therapy’ patient population;Journal of the Neurological Sciences;2024-09
2. Age-corrected neurofilament light chain ratio decreases but does not predict relapse in highly active multiple sclerosis patients initiating natalizumab treatment;Multiple Sclerosis and Related Disorders;2024-08
3. Natalizumab treatment of multiple sclerosis — a Danish nationwide study with 13 years of follow-up;Multiple Sclerosis and Related Disorders;2023-06
4. Real-World Data Regarding Long-Term Administration of Natalizumab Derived from a Neurology Department along with Literature Review;CNS & Neurological Disorders - Drug Targets;2022-05
5. PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective study;Journal of Neurology;2021-06-28
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3